Next Article in Journal / Special Issue
Mucins and Pancreatic Cancer
Previous Article in Journal
Breast Cancer: Surgery at the South Egypt Cancer Institute
Previous Article in Special Issue
Interaction of Stellate Cells with Pancreatic Carcinoma Cells
Article Menu

Export Article

Open AccessArticle
Cancers 2010, 2(4), 1779-1793; doi:10.3390/cancers2041779

CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer

Department of General Surgery, Henry Ford Health System, Detroit, MI 48202, USA
Department of Diagnostic Radiology, Henry Ford Health System, Detroit, MI 48202, USA
Department of Radiation Oncology, Henry Ford Health System, Detroit, MI 48202, USA
Author to whom correspondence should be addressed.
Received: 10 September 2010 / Revised: 8 October 2010 / Accepted: 11 October 2010 / Published: 13 October 2010
(This article belongs to the Special Issue Pancreatic Cancer)
View Full-Text   |   Download PDF [2299 KB, uploaded 13 October 2010]   |  


Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human malignancy with dismal prognosis and few effective therapeutic options. Novel agents that are safe and effective are urgently needed. Oleanolic acid-derived synthetic triterpenoids are potent antitumorigenic agents, but their efficacy or the mechanism of action for pancreatic cancer has not been adequately investigated. In this study, we evaluated the antitumor activity and the mechanism of action of methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (CDDO-Me), a oleanane-derived synthetic triterpenoid for human pancreatic cancer cell lines. CDDO-Me inhibited the growth of both K-ras mutated (MiaPaca2, Panc1 and Capan2) and wild-type K-ras (BxPC3) pancreatic cancer cells at very low concentrations. The growth inhibitory activity of CDDO-Me was attributed to the induction of apoptosis characterized by increased annexin-V-FITC binding and cleavage of PARP-1 and procaspases-3, -8 and-9. In addition, CDDO-Me induced the loss of mitochondrial membrane potential and release of cytochrome C. The antitumor activity of CDDO-Me was associated with the inhibition of prosurvival p-Akt, NF-κB and mammalian target of rapamycin (mTOR) signaling proteins and the downstream targets of Akt and mTOR, such as p-Foxo3a (Akt) and p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR). Silencing of Akt or mTOR with gene specific-siRNA sensitized the pancreatic cancer cells to CDDO-Me, demonstrating Akt and mTOR as molecular targets of CDDO-Me for its growth inhibitory and apoptosis-inducing activity. View Full-Text
Keywords: pancreatic cancer; CDDO-Me; apoptosis; Akt/mTOR signaling pathway pancreatic cancer; CDDO-Me; apoptosis; Akt/mTOR signaling pathway

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Deeb, D.; Gao, X.; Arbab, A.S.; Barton, K.; Dulchavsky, S.A.; Gautam, S.C. CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer. Cancers 2010, 2, 1779-1793.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top